Hone Health
Hone Health, at-home-testing-to-TRT telehealth
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Platform; prescribes FDA-approved testosterone off a telehealth workflow
Reference only. Not medical advice.
What can go wrong
TRT is a lifelong medical therapy with documented effects on fertility (suppression of spermatogenesis), hematocrit, and cardiovascular monitoring needs. A model that profits from initiation and retention has an incentive misaligned with conservative prescribing. Consumer complaints reported around labs, billing, and post-cancellation charges reflect operational, not just clinical, risk.
This is something to take to a clinician. The Atlas can tell you what is known about hone health in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Hone Health is a telehealth company built around at-home hormone testing that feeds directly into a testosterone-replacement subscription. Its model pairs an at-home or in-home blood draw with physician consults and a membership (reported around $120-$130/month) that unlocks testosterone injections and ancillaries like anastrozole. Hone raised a $33M Series A in January 2025 led by Tribe Capital (with the Saudi Public Investment Fund and others), coinciding with its acquisition of in-home phlebotomy provider ivee; a reported valuation near $189M. Third-party estimates (Sacra) put ARR around $70M at end-2024 growing past $110M in 2025.
The company that both runs the test and sells the treatment the test justifies.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
The core mechanic is vertical integration of diagnosis and treatment: Hone controls the test that establishes eligibility for the very therapy it then sells and refills. Because TRT is typically lifelong, the model has high customer lifetime value driven by retention, not just acquisition.
The built-in conflict
When one company owns both the diagnostic that defines 'low' and the prescription that treats it, the incentive runs toward finding more men eligible and keeping them on therapy indefinitely. This is the structural conflict at the heart of the testing-to-treatment vertical: the seller sets, or at least frames, the threshold for the sale. It does not mean any individual diagnosis is wrong, but it is why independent confirmation of a genuine, symptomatic, repeatedly-low testosterone level matters.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
Replacement is not the same as a cycle
Legitimate TRT targets restoration of testosterone to a normal physiological range. Risk escalates sharply if dosing drifts into supraphysiological (anabolic) territory; a commercial incentive to keep customers 'optimized' can push toward higher-than-replacement targets that carry erythrocytosis and cardiovascular risk.
What it does to fertility
Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and reduces sperm production; TRT can impair fertility and is generally inappropriate for men actively seeking conception.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total and free testosterone
- Hematocrit / hemoglobin
- Estradiol
- PSA (age-appropriate)
- Lipids and blood pressure
What people get wrong
Often saidAn at-home test is enough to start lifelong TRT
ActuallyA single at-home result is a screening signal, not a diagnosis. Guideline-concordant diagnosis of hypogonadism requires repeat morning fasting measurements plus symptoms, and evaluation of secondary causes.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Founders and venture backers (Tribe Capital, Saudi PIF, Republic Capital, and others). Revenue is recurring subscription plus pharmacy and lab margin.
At a glance
- Model
- At-home testing -> TRT subscription
- Series A
- $33M (Jan 2025), led by Tribe Capital
- Reported valuation
- ~$189M
- Acquisition
- ivee (in-home phlebotomy), 2025
- ARR (est.)
- ~$70M end-2024, >$110M 2025 (Sacra)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Hone Health. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.